CSL (CSL.AX) share price
CSL (ASX:CSL.AX) last traded at AUD 202.04, down 0.18% on the day, with a market cap of INR 9695.6 Cr.
| Exchange | ASX |
|---|---|
| Currency | AUD |
| Last price | AUD 202.04 |
| 1-day move | -0.18% |
| Market cap | INR 9695.6 Cr |
| Falling Shares risk score | 25/100 (Watch) |
| Sector | Healthcare |
| Industry | Biotechnology |
| 1-month move | n/a |
| 1-year move | n/a |
| Statutory auditor | n/a |
| Credit rating | AAA / Stable |
| Promoter pledge | n/a |
CSL Limited is a global biotechnology leader developing biotherapies for rare diseases and influenza prevention vaccines via its CSL Behring and Seqirus operations. The enterprise is actively monitored for corporate governance anomalies, working capital stress, debt service coverage, and operational headwinds. Recent trading patterns and financial disclosures reflect ongoing sector adjustments and market-moving developments.
From a regulatory and fiduciary oversight perspective, CSL is subject to periodic statutory filings, independent financial audits, and regulatory disclosure mandates under ASX listing requirements. Investors and analysts evaluate ongoing risk factors and liquidity reserves prior to making capital allocation decisions.
Governance flags
- Standard Trading Velocity
Frequently asked questions
Why is CSL falling today?
CSL (ASX:CSL.AX) is down 0.18% at its latest quote. A price fall alone does not identify a cause: Falling Shares Intelligence links a move to a filing, order or news item only when a source supports it.
What is the CSL share price today?
CSL (ASX:CSL.AX) last traded at AUD 202.04, a -0.18% move on the day. Market data comes from public feeds and may be delayed; it is not investment advice.
What is the market cap of CSL?
CSL has a market capitalisation of about INR 9695.6 Cr at the latest price.
What are the risks of investing in CSL?
Falling Shares Intelligence rates CSL 25/100 (Watch) on price stress, volume and disclosure signals; flagged governance items: Standard Trading Velocity. Risk scores are analytical indicators, not allegations or investment advice. Review exchange filings and the company's own disclosures before any decision.
Data is compiled from public exchange feeds and may be delayed. Not investment advice.
Wung Thomas, Editor-in-Chief: wungthomas@fallingshares.com. General enquiries and corrections: info@fallingshares.com